JPH08507604A - ｈＣＧまたはｈＣＧのフラグメントを分泌する癌に対する診断用キットおよびかような癌の免疫療法用手段 - Google Patents
ｈＣＧまたはｈＣＧのフラグメントを分泌する癌に対する診断用キットおよびかような癌の免疫療法用手段Info
- Publication number
- JPH08507604A JPH08507604A JP6519675A JP51967594A JPH08507604A JP H08507604 A JPH08507604 A JP H08507604A JP 6519675 A JP6519675 A JP 6519675A JP 51967594 A JP51967594 A JP 51967594A JP H08507604 A JPH08507604 A JP H08507604A
- Authority
- JP
- Japan
- Prior art keywords
- hcg
- polypeptide
- polypeptides
- primary sequence
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 40
- 239000012634 fragment Substances 0.000 title claims abstract description 30
- 230000003248 secreting effect Effects 0.000 title claims abstract description 18
- 238000009169 immunotherapy Methods 0.000 title claims abstract description 15
- 238000009007 Diagnostic Kit Methods 0.000 title claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 122
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 117
- 229920001184 polypeptide Polymers 0.000 claims abstract description 115
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 34
- 238000012360 testing method Methods 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 17
- 230000003053 immunization Effects 0.000 claims description 15
- 238000002649 immunization Methods 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 11
- 231100000135 cytotoxicity Toxicity 0.000 claims description 6
- 230000003013 cytotoxicity Effects 0.000 claims description 6
- 230000001571 immunoadjuvant effect Effects 0.000 claims description 6
- 239000000568 immunological adjuvant Substances 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000002405 diagnostic procedure Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 201000005112 urinary bladder cancer Diseases 0.000 description 9
- 206010005003 Bladder cancer Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 5
- 229920001917 Ficoll Polymers 0.000 description 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 4
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 4
- 102000009151 Luteinizing Hormone Human genes 0.000 description 4
- 108010073521 Luteinizing Hormone Proteins 0.000 description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 description 4
- 102000011923 Thyrotropin Human genes 0.000 description 4
- 108010061174 Thyrotropin Proteins 0.000 description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 description 4
- 229940040129 luteinizing hormone Drugs 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 206010004272 Benign hydatidiform mole Diseases 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 208000006937 Hydatidiform mole Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000032692 embryo implantation Effects 0.000 description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 201000008814 placenta cancer Diseases 0.000 description 1
- 208000024361 placenta neoplasm Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9302820A FR2702494B1 (fr) | 1993-03-11 | 1993-03-11 | Trousse de diagnostic d'un cancer secrétant l'hCG ou des fragments d'hCG et vaccin destiné à l'immunothérapie d'un tel cancer. |
| FR93/02820 | 1993-03-11 | ||
| FR93/12039 | 1993-10-08 | ||
| FR9312039A FR2710845B1 (fr) | 1993-10-08 | 1993-10-08 | Composition destinée à l'immunothérapie d'un cancer sécrétant l'hCG ou des fragments d'hCG. |
| PCT/FR1994/000265 WO1994020859A1 (fr) | 1993-03-11 | 1994-03-10 | TROUSSE DE DIAGNOSTIC D'UN CANCER SECRETANT L'hCG OU DES FRAGMENTS D'hCG ET MOYENS DESTINES A L'IMMUNOTHERAPIE D'UN TEL CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH08507604A true JPH08507604A (ja) | 1996-08-13 |
Family
ID=26230164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6519675A Pending JPH08507604A (ja) | 1993-03-11 | 1994-03-10 | ｈＣＧまたはｈＣＧのフラグメントを分泌する癌に対する診断用キットおよびかような癌の免疫療法用手段 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0688432A1 (de) |
| JP (1) | JPH08507604A (de) |
| AU (1) | AU6211294A (de) |
| CA (1) | CA2157868A1 (de) |
| NZ (1) | NZ262435A (de) |
| WO (1) | WO1994020859A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677275A (en) * | 1994-08-05 | 1997-10-14 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of cancer with human chorionic gonadotropin |
| FR2745638A1 (fr) * | 1996-03-04 | 1997-09-05 | Roussy Inst Gustave | Procede pour la detection de la transformation maligne de cellules humaines |
| US5968513A (en) * | 1996-06-24 | 1999-10-19 | University Of Maryland Biotechnology Institute | Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin |
| US5997871A (en) * | 1996-06-24 | 1999-12-07 | University Of Maryland Biotechnology Insitute | Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin |
| US6319504B1 (en) | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
| US6583109B1 (en) | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
| US7994278B1 (en) * | 1999-08-06 | 2011-08-09 | Nobel Biosciences Llc | Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4201770A (en) * | 1973-05-07 | 1980-05-06 | The Ohio State University | Antigenic modification of polypeptides |
| US4234561A (en) * | 1978-02-06 | 1980-11-18 | Research Corporation | Antigen for early pregnancy test and contraceptive vaccine |
| US4713366A (en) * | 1985-12-04 | 1987-12-15 | The Ohio State University Research Foundation | Antigenic modification of polypeptides |
| FR2623715B1 (fr) * | 1987-11-26 | 1990-12-21 | Lafon Labor | Structures peptidiques, immunogenes les contenant et leurs applications au controle de la fertilite |
| GB8821507D0 (en) * | 1988-09-14 | 1988-10-12 | Cancer Res Campaign Tech | Improvements relating to peptides |
| EP0553301A1 (de) * | 1990-10-17 | 1993-08-04 | Yale University | Verfahren zum nachweis und zur verlaufsverfolgung von krebs, schwangerschaft und krankheit des trophoblasten |
-
1994
- 1994-03-10 NZ NZ262435A patent/NZ262435A/en unknown
- 1994-03-10 JP JP6519675A patent/JPH08507604A/ja active Pending
- 1994-03-10 EP EP94909172A patent/EP0688432A1/de not_active Withdrawn
- 1994-03-10 CA CA002157868A patent/CA2157868A1/fr not_active Abandoned
- 1994-03-10 AU AU62112/94A patent/AU6211294A/en not_active Abandoned
- 1994-03-10 WO PCT/FR1994/000265 patent/WO1994020859A1/fr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0688432A1 (de) | 1995-12-27 |
| WO1994020859A1 (fr) | 1994-09-15 |
| AU6211294A (en) | 1994-09-26 |
| NZ262435A (en) | 1997-05-26 |
| CA2157868A1 (fr) | 1994-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Salgaller et al. | Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides | |
| Yamamoto et al. | MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer | |
| EP1210430B1 (de) | Von MUC-1 abgeleitete Peptide | |
| CN1921878B (zh) | 属于Bcl-2家族的蛋白和其片段,和它们在癌症患者中的用途 | |
| Hershman et al. | Extraction and characterization of a thyrotropic material from the human placenta | |
| EP2336772B1 (de) | Verfahren zur prognose des schwangerschaftsausganges bei einer mit einem hcg-test untersuchten person | |
| EP1183390B8 (de) | Methoden zur vohersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests | |
| JPH09501159A (ja) | 合成多重縦列反復ムチンおよびムチン様ペプチド、並びにそれらの利用 | |
| Dubois et al. | Immunocytological localization of LH, FSH, TSH and their subunits in the pituitary of normal and anencephalic human fetuses | |
| SK12412000A3 (sk) | Metódy liečenia diabetu použitím peptidových analógov inzulínu | |
| JPH08507604A (ja) | ｈＣＧまたはｈＣＧのフラグメントを分泌する癌に対する診断用キットおよびかような癌の免疫療法用手段 | |
| JP5706895B2 (ja) | がんペプチドワクチン | |
| CA1057742A (en) | Antigenic modification of polypeptides | |
| ODELL et al. | Endocrine aspects of trophoblastic neoplasms | |
| Metz et al. | Ectopic secretion of chorionic gonadotropin by a lung carcinoma: Pituitary gonadotropin and subunit secretion and prolonged chemotherapeutic remission | |
| GB2135882A (en) | Material for use in the treatment of spontaneous abortions | |
| US6217881B1 (en) | Antigenic modification of HCG polypeptides | |
| US20020031531A1 (en) | Immunogenic tlp composition | |
| CN101189259A (zh) | 卵泡刺激素超激动剂 | |
| Colombo et al. | Three-step immunoscintigraphy with anti-chromogranin A monoclonal antibody in tumours of the pituitary region | |
| Aloia et al. | Parathyroid function in acromegaly | |
| CN116261450A (zh) | 癌症肽疫苗及其制备方法 | |
| JPH10506877A (ja) | ライグラス花粉アレルゲンのｔ細胞エピトープ | |
| Benveniste et al. | Alpha subunit of glycoprotein hormone: Presence in peripheral serum after LHRH | |
| EP1221964B1 (de) | Antigene modifikation von polypeptiden |